Mabvax Therapeutics Holdings Inc (MBVX) 1.0600 $MBVX
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.80 (-0.18), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
OPKO Health, Inc. Participates in Latest Round of Financing for MabVax Therapeutics
Marketwired - Thu Oct 08, 7:02AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"
, a clinical-stage cancer immunotherapy company, previously announced that it has closed its public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock. OPKO Health (NYSE: OPK) participated in the financing and was one of the largest investors in the round. This is the second investment made by OPKO Health, Inc. this year in MabVax.
OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings, Inc. Announces Closing of Public Offering
PR Newswire - Mon Oct 05, 3:31PM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" , a clinical-stage immuno-oncology drug development company, today announced that it has closed its previously announced public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock. For every two shares of common stock sold, MabVax issued one warrant to purchase one share of common stock. The shares and warrants were separately issued. The warrants are immediately exercisable, expire September 30, 2018 and have an exercise price of $1.32 per share. The warrants will not be listed on any securities exchange or other trading market. The public offering price of the common stock was $1.10 per share. Gross proceeds to MabVax are approximately $2.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MabVax.
MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering
PR Newswire - Wed Sep 30, 8:39AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" , a clinical-stage immuno-oncology drug development company, today announced the pricing of its public offering of 2,500,000 shares of its common stock at an offering price to the public of $1.10 per share and warrants to purchase up to 1,250,000 shares of its common stock at an offering price to the public of $0.01 per warrant. All shares of common stock and warrants are being offered by MabVax. For every two shares of common stock sold, MabVax will issue one warrant to purchase one share of common stock. The shares and warrants will be separately issued, although they will be issued and sold in equal proportions. The warrants are immediately exercisable, expire September 30, 2018 and have an exercise price of $1.32 per share. The warrants will not be listed on any securities exchange or other trading market.
Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.04 (+0.05), AAAP: (), MACK: 9.60 (+0.17), PGNX: 5.77 (+0.26), APTO: 4.14 (+0.03), BLCM: 14.65 (+0.39), RXDX: 10.36 (-0.03), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), JUNO: 48.64 (+0.84), CBLI: 4.53 (+0.07), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
MabVax Therapeutics Holdings Provides Corporate Update and Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, today provided a corporate update and reported financial results for the quarter ended June 30, 2015.
OPK: 8.90 (+0.26)
MabVax Therapeutics and The Rockefeller University Enter Into a Collaborative Research Agreement
PR Newswire - Thu Aug 06, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, and The Rockefeller University's Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region (Fc) variants of the HuMab 5B1 in the role of tumor clearance. The objective is to optimize Fc receptor mediated antibody function.
MabVax Therapeutics Issues Letter to Stockholders
PR Newswire - Wed Aug 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company" , a clinical stage immuno-oncology drug development company, announces the posting of the following Letter to Stockholders from President and Chief Executive Officer David Hansen to the Company's website at www.mabvax.com
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 12.80 (+1.06), NBS: 2.25 (-0.09), CLSN: 1.84 (+0.14), JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40), EXEL: 5.99 (+0.14), ONCY: 0.45 (unch), CERU: 3.65 (+0.07), PFE: 33.24 (+0.15), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), CLVS: 93.60 (+3.62), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)
MabVax Therapeutics - "When is a Fully Human Antibody Really Fully Human"
ACCESSWIRE - Thu Jul 16, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 16, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
ACCESSWIRE - Wed Jul 01, 1:16PM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds
Marketwired - Wed Jul 01, 6:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company" , a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015.
OPK: 8.90 (+0.26)
MabVax's HuMab 5B1 Toxicology Results In Context
Mayer Winkler - at Seeking Alpha - Thu Jun 11, 9:52AM CDT
OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT
PR Newswire - Thu May 28, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.
MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015 Financial Results
Marketwired - Fri May 15, 7:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, provided today a corporate update and reported financial results for the first quarter ended March 31, 2015.
OPK: 8.90 (+0.26)
MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing
PR Newswire - Tue May 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent contract research organization. The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. These results further validate the Company's decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of 2015.
With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 28, 6:30AM CDT
OPK: 8.90 (+0.26), TEVA: 58.96 (-0.28)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.80 (-0.18), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
OPKO Health, Inc. Participates in Latest Round of Financing for MabVax Therapeutics
Marketwired - Thu Oct 08, 7:02AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"
, a clinical-stage cancer immunotherapy company, previously announced that it has closed its public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock. OPKO Health (NYSE: OPK) participated in the financing and was one of the largest investors in the round. This is the second investment made by OPKO Health, Inc. this year in MabVax. OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings, Inc. Announces Closing of Public Offering
PR Newswire - Mon Oct 05, 3:31PM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax"
, a clinical-stage immuno-oncology drug development company, today announced that it has closed its previously announced public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock. For every two shares of common stock sold, MabVax issued one warrant to purchase one share of common stock. The shares and warrants were separately issued. The warrants are immediately exercisable, expire September 30, 2018 and have an exercise price of $1.32 per share. The warrants will not be listed on any securities exchange or other trading market. The public offering price of the common stock was $1.10 per share. Gross proceeds to MabVax are approximately $2.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MabVax. MabVax Therapeutics Holdings, Inc. Announces Pricing of Public Offering
PR Newswire - Wed Sep 30, 8:39AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax"
, a clinical-stage immuno-oncology drug development company, today announced the pricing of its public offering of 2,500,000 shares of its common stock at an offering price to the public of $1.10 per share and warrants to purchase up to 1,250,000 shares of its common stock at an offering price to the public of $0.01 per warrant. All shares of common stock and warrants are being offered by MabVax. For every two shares of common stock sold, MabVax will issue one warrant to purchase one share of common stock. The shares and warrants will be separately issued, although they will be issued and sold in equal proportions. The warrants are immediately exercisable, expire September 30, 2018 and have an exercise price of $1.32 per share. The warrants will not be listed on any securities exchange or other trading market. Neuroblastoma Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Neuroblastoma
M2 - Mon Aug 17, 8:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9kbwkd/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2015" report to their offering. Summary This, Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Aeterna Zentaris Inc. - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - Aptose Biosciences Inc. - AstraZeneca Plc - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - Gamida Cell Ltd. - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Netris Pharma S.A.S. - Novartis AG - Novogen Limited - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/9k...roblastoma
AMPE: 3.04 (+0.05), AAAP: (), MACK: 9.60 (+0.17), PGNX: 5.77 (+0.26), APTO: 4.14 (+0.03), BLCM: 14.65 (+0.39), RXDX: 10.36 (-0.03), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), JUNO: 48.64 (+0.84), CBLI: 4.53 (+0.07), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
MabVax Therapeutics Holdings Provides Corporate Update and Reports Second Quarter 2015 Financial Results
PR Newswire - Mon Aug 10, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, today provided a corporate update and reported financial results for the quarter ended June 30, 2015.
OPK: 8.90 (+0.26)
MabVax Therapeutics and The Rockefeller University Enter Into a Collaborative Research Agreement
PR Newswire - Thu Aug 06, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, and The Rockefeller University's Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region (Fc) variants of the HuMab 5B1 in the role of tumor clearance. The objective is to optimize Fc receptor mediated antibody function.
MabVax Therapeutics Issues Letter to Stockholders
PR Newswire - Wed Aug 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"
, a clinical stage immuno-oncology drug development company, announces the posting of the following Letter to Stockholders from President and Chief Executive Officer David Hansen to the Company's website at www.mabvax.com Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 12.80 (+1.06), NBS: 2.25 (-0.09), CLSN: 1.84 (+0.14), JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40), EXEL: 5.99 (+0.14), ONCY: 0.45 (unch), CERU: 3.65 (+0.07), PFE: 33.24 (+0.15), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), CLVS: 93.60 (+3.62), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), NVS: 91.90 (-0.71)
MabVax Therapeutics - "When is a Fully Human Antibody Really Fully Human"
ACCESSWIRE - Thu Jul 16, 7:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 16, 2015 / MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, David Hansen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
ACCESSWIRE - Wed Jul 01, 1:16PM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds
Marketwired - Wed Jul 01, 6:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"
, a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015. OPK: 8.90 (+0.26)
MabVax's HuMab 5B1 Toxicology Results In Context
Mayer Winkler - at Seeking Alpha - Thu Jun 11, 9:52AM CDT
OPK: 8.90 (+0.26)
MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT
PR Newswire - Thu May 28, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.
MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015 Financial Results
Marketwired - Fri May 15, 7:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, provided today a corporate update and reported financial results for the first quarter ended March 31, 2015.
OPK: 8.90 (+0.26)
MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing
PR Newswire - Tue May 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent contract research organization. The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. These results further validate the Company's decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of 2015.
With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 28, 6:30AM CDT
OPK: 8.90 (+0.26), TEVA: 58.96 (-0.28)
